Swing Trade Ideas

 🏃🚀BYND high 1.55, up 93%  

🏃🚀CMND high 1.44, over 100%, 2nd time, rinse and repeat  

 🏃🚀 AMC high 1.91, up 80%   

🏃🚀 TMDE 73%🚀 

 ✅ NNOX entry: 1.70
🎯 PT1: 1.90–2.40
🎯 PT2: 2.50–2.80
🎯 PT3: 2.90–3.70
🚫 Stop: Below 1.65 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to near 52wk low, recently announced securing  FDA 510 (K) clearance for TAP2D Image enhancement on Nanox ARC systems, recent new collaboration announcement with Adriamed d.o.o Beograd,  company develops medical imaging systems, D. Boral price target $8, 

 ✅ HCAT entry: 1.30–1.40
🎯 PT1: 1.50–1.80
🎯 PT2: 1.90–2.70
🎯 PT3: 2.80–3.50
🚫 Stop: Below 1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to support near 52wk low, company focuses on healthcare data analytics and technology, providing cloud based data operating system and analytic tools to hospitals and health systems, Citigroup price target $2.75, Stifel price target $3.75 

 ✅ HUMA entry: 0.70–0.80
🎯 PT1: 1.10–1.60 🎯 PT2: 1.70–2.40 🎯 PT3: 2.50–3.60
🚫 Stop: Below 0.55 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 company develops off-the=shelf, implantable bioengineered huma tissues designed to improve treatment of vascular and organ damage, plan to file MAA with Israel Ministry of Health for approval of Acellular Tissue engineered vessel for Arterial Trauma Repair, BTIG price target $3, TD Cowen price target $1, D. Boral capital price target $25, does have mixed shelf, be mindful on next spike 

 ✅ ONCY entry: 0.90
🎯 PT1: 1.20–1.80 🎯 PT2: 1.90–2.50 🎯 PT3: 2.60–3.80
🚫 Stop: Below 0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to support from recent high, company focuses on the development of first in class intravenously delivered oncolytic virus designed to selectively destroy cancer cells and stimulate the immune system against tumors, previously announced promising Pelareorep data in colorectal cancer, FDA recently agreed on phase 3 trial design for elareorep in pancreatic cancer, planning to launch immunotherapy trial in pancreatic cancer in 2026,  Lake Street buy rating,  RBC Capital buy rating, HC Wainwright raised target price to $10 from $5, director James T. Parsons recently acquired shares 

 ✅ PEPG entry: 1.45–1.50
🎯 PT1: 1.70–2.30 🎯 PT2: 2.40–2.80 🎯 PT3: 2.90–3.50
🚫 Stop: Below 1.10 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 Wedbush buy rating price target $5, Guggenhein buy rating price target $7, Oppenheimer buy rating price target $15, HC Wainwright price target $14, Stifel Nicolaus buy rating on promising advances in DMD (Duchenne muscular dystrophy and DM1 (Myotonic dystrophy type 1) programs, DMD company focusing on developing next-generation oligonucleotide therapeutics to treat severe neuromuscular and neurological diseases 

 ✅ FCUV potential entry: 1.30
🎯 PT1: 1.45–1.70 🎯 PT2: 1.80–2.50 🎯 PT3: 2.60–2.70
🚫 Stop: Below 1.25 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 ultra small float, company focuses on Internet of Things (IoT) devices, smart sensors, automation systems, AI-driven financial reporting software, recently completed major Monterey Park Property Acquisition 

✅ TMDE potential entry: $1.20

🎯 PT1: $1.40 – $1.80 🎯 PT2: $1.90 – $2.40 🎯 PT3: $2.50 – $2.80

🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical Setup

 small float, previously announced partnership with Double Corporate for Green Bioenergy Expansion, previously announced expansion into oil waste collection, company specializes in the supply and marketing of marine gas oil and marine fuel oil based in Malaysia and Singapore,, also offers ship management services and vessels chartering. recent IPO 

✅ MAIA potential entry: 1.20

🎯 PT1: 1.80 – 2.30 🎯 PT2: 2.40 – 2.80 🎯 PT3: 3.00 – 3.50

🚫 Stop: Below 1.00 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-driven

 Near 52wk low from recent high, recent offering price at $1.50 per share, previously secured European patent for cancer therapy, received FDA fast track designation for Ateganosie for its treatment of non-small cell lung cancer, recently announced agreement with ROCHE for cancer therapies, recently announced positive phase 2 clinical trial, Noble Financial price target $14, company focuses on novel telomere-targeting drug called THIO (ateganosine), aimed at telemerase-positive cancers, especially non-small cell lunch cancer (NSCLC) and pediatric high-trade gliomas, operates multiple clinical-stage programs with a team based in Chicago, 

  ⏳⏳ SMS swing alert: ✅  CMND entry: .65–.70
🎯 PT1: 1.0–1.50 🎯 PT2: 1.60–1.90 🎯 PT3: 2–2.60
🚫 Stop: Below .60 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 recently announced evaluation of CMND-100 for breakthrough therapy designation in alcohol use disorder trial, the President recently announced signing order on psychedelic used for PTSD, also recently filed patent application in India for psychedelic-based compounds for treatment of mental health disorders and addiction, also granted 6 therapy patents in Hong Kong, previously reported positive data for CMND - 100 in alcohol use disorder trial, recently enrolled last patient for first cohort of CMND-100 trial for the treatment of AUD (alcohol use disorder) , recently filed and announced publication of US patent application on binge drinking addiction and compulsive behaviors, also established international patent application for therapy targeting obesity and metabolic syndrome in collaboration with SciSparc, also recently secured IRB approval from Hadassah Medical Center for phase 1/2a trial of Novel AUD treatment, company focuses on the development of psychedelic-derived therapeutics for mental health, neurological disorders, lead candidate, CMND-100 for alcohol use disorder (AUD 

 ⏳⏳ SMS swing alert: ✅ BYND entry: .80
🎯 PT1: 1.20–1.90 🎯 PT2: 2.05–3.80 🎯 PT3: 3.90–4.50
🚫 Stop: Below .70 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 recently announced rolling out new Beyond Chicken Pieces variety at Kroger $KR stores recently launched latest Beyond Burger at Hard Rock Cafe and introduced Beyond Beef at retailers across Canada, company produces plant-based meat alternatives, does have mixed shelf 

✅ $ONCO entry: $.65–.70

🎯 PT1: $1.00–$1.40
🎯 PT2: $1.50–$2.80
🎯 PT3: $2.90–$3.30

🚫 Stop: Below $.60 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical Setup

 company focuses on prostate cancer diagnostic test, recently 1/5 reverse split, ultra small float, recent Realbotix acquisition expected to close in 2nd half of 2026, 

  ✅ FLD potential entry: $1.35 – $1.45
🎯 PT1: $1.70 – $2.30
🎯 PT2: $2.40 – $2.80
🎯 PT3: $2.90 – $3.50
🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to suport, recently launched No annual fee credit card with up to 4% $BTC.X back monthly , company operates a bitcoin-financial-services platform that enables consumers to earn, save, and use $BTC.X via consumer financial products, recently partnered with Steak n' Shake for BTC.X promotion, CEO previously announced wanting BTC.X gift card to be available in holiday season, Cantor Fitzgerald price target $6.50,  Leerink partners price target $14.5, does have mixed shelf, be mindful on next spike, 

  ✅ NRSN entry: .65
🎯 PT1: 0.80 – 1.40
🎯 PT2: 1.50 – 1.80
🎯 PT3:1.90 – 2.50
🚫 Stop: Below 0.60 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
back to near 52wk low, recently announced positive trial results for Alzheimer's drug candidate, D. Boral Capital price target $14, Noble financial buy rating, Alliance Global Partners buy rating,  its leading drug candidate, PrimeC, a combination of ciprofloxacin and celecoxib for amyotrophic lateral sclerosis (ALS) has shown positive clinical data in phase 2b, currently being prepared for commercial-scale production, upcoming catalyst: 1) topline data, phase 3, 2nd of half 2026, 2) full lNDS submission later of 2026, 3) phase 2 alzheimer's trial top line expected 2026, company focuses on neurodegenerative diseases, primarily ALS, with additional pipeline programs targeting Alzheimer's and Parkinson's, does have mixed shelf,  

   ✅ CGC entry: 1.20–1.30
🎯 PT1: 1.50–1.90 🎯 PT2: 2.00–2.70 🎯 PT3: 2.80–3.70
🚫 Stop: Below 1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 mj ticker , one of the largest Canadian cannabis companies focuses on production, distribution, and sale of medical and recreational cannabis, also carries non-THC products including hemp-derived wellness goods, Bernstein price target $2.50, 

 ✅ SNDL entry: 1.50–1.60
🎯 PT1: 1.80–2.50 🎯 PT2: 2.60–3.50 🎯 PT3: 3.60–4.40
🚫 Stop: Below 1.25 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
MJ related ticker, recently amended agreement to acquire Cannabis Retail stores, company produces, distributes, and sells cannabis products, analyst rating price target $5 

   ✅ ARAI entry: .85–.90
🎯 PT1: 1.10–1.80 🎯 PT2: 1.90–2.40 🎯 PT3: 2.50–2.80
🚫 Stop: Below .80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 recently appointed T-Mobile executive Michael Fitz to board, secured patent for shared-use autonomous delivery endpoints, has until 9/28/2026 to regain compliance with NASDAQ by bringing shares to min market value, above 50 million for at least 10 consecutive business days, company builds smart delivery infrastructure, designed for robots, drones, and humans to exchange packages with a focus on last-mile logistics, healthcare delivery and automation, Maxim Group buy rating, does have mixed shelf 

 ✅ NNVC entry: 1.15–1.20
🎯 PT1: 1.40–1.80 🎯 PT2: 1.90–2.50 🎯 PT3: 2.60–3.30
🚫 Stop: Below 1.0 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 recently announced completed manufacture of NV-387 oral gummies, filed application for orphan drug designation for NV-387 to treat measles, recently signed Master services agreements with Only Orphans Cote, company focuses on discovering and developing broad-spectrum antiviral therapeutics, former runner, Alliance Global buy rating 

  ✅ $PRSO potential entry: .90-.95

🎯 Potential PT1: $1.20 -1.80, 🎯 PT2: $1.90–$2.50, 🎯 PT3: $2.60–$3.50
🚫 Potential Stop: Below $.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

recently announced delivery shipment of 60GHz modules for drone IFF systems, previously announced collaboration with Virewirx, previously secured $1.1M through inducement offer agreement, ,secured $0.9M order from FWA equipment supplier, partnered with WeLink to expand access to high-speed broadband across dense US metro areas, company focuses on fabless semiconductor/mmWave wireless technology, , Benchmark Co buy rating, price target $3

 ✅ $STAK entry: $0.90–$
🎯 PT1: $1.20–$1.70 🎯 PT2: $1.80–$2.20 🎯 PT3: $2.30–$2.80
🚫 Stop: Below $0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 recently regained compliance,  back to near 52wk low from 52wk high above 4.50, company focused on research, development, manufacturing and sale of specialized oil-field production & maintenance equipment 

 ⏳⏳ SMS swing alert: ✅  CMND entry: .65–.70
🎯 PT1: 1.0–1.50 🎯 PT2: 1.60–1.90 🎯 PT3: 2–2.60
🚫 Stop: Below .60 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

the President recently announced signing order on psychedelic used for PTSD, also recently filed patent application in India for psychedelic-based compounds for treatment of mental health disorders and addiction, also granted 6 therapy patents in Hong Kong, previously reported positive data for CMND - 100 in alcohol use disorder trial, recently enrolled last patient for first cohort of CMND-100 trial for the treatment of AUD (alcohol use disorder) , recently filed and announced publication of US patent application on binge drinking addiction and compulsive behaviors, also established international patent application for therapy targeting obesity and metabolic syndrome in collaboration with SciSparc, also recently secured IRB approval from Hadassah Medical Center for phase 1/2a trial of Novel AUD treatment, company focuses on the development of psychedelic-derived therapeutics for mental health, neurological disorders, lead candidate, CMND-100 for alcohol use disorder (AUD)

 ⏳⏳ SMS swing alert: ✅ BYND entry: .80
🎯 PT1: 1.20–1.90 🎯 PT2: 2.05–3.80 🎯 PT3: 3.90–4.50
🚫 Stop: Below .70 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 recently launched latest Beyond Burger at Hard Rock Cafe and introduced Beyond Beef at retailers across Canada, company produces plant-based meat alternatives, does have mixed shelf, be mindful on next spike 

 ⏳⏳ SMS swing alert: ✅ FRGT potential entry: $0.80–$0.85
🎯 Potential PT1: $1.20–$2.20 🎯 PT2: $2.30–$2.80 🎯 PT3: $2.90–$3.70
🚫 Potential Stop: Below $0.75 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 small float, recently announced rolling out AI customs compliance platform DOA Smart for Mexico, previously launched of Zayren Pro with next-generation AI agents, recently announced acquisition of JAK Solar,  previous 13g filing shows ATW Fund 9.9% stake, company focuses on building AI-powered freight and supply-chain software, including digital platforms for freight booking and tracking, border shipping apps, transportation management systems (TMS), and real-time GPS/visibility tools across the US and Mexico 

 ⏳⏳ SMS swing alert: ✅ MRM entry: $1.10–$1.20
🎯 PT1: $1.40–$1.80 🎯 PT2: $1.90–$2.40 🎯 PT3: $2.50–$3.90
🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 recently launched partnership with Tools for Humanity recently announced that Proof of Human authentications surpasses 20,000 in partnership with WORLD FOUNDATION, co-founded by Sam Altman and Alex Blania, company is a Japan-based holistic healthcare, does have mixed shelf, be mindful on next spike, 

✅ CGTX potential entry: $1.05

🎯 PT1: $1.40 – $1.80
🎯 PT2: $1.90 – $2.70
🎯 PT3: $2.80 – $3.50

🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 clinical stage biopharmaceutical company focuses on age-related neurodegenerative diseases specifically Alzheimer's and dementia with Lew bodies, lead candidate is zervimesine (CT1812), oral formulation designed to penetrate the blood-brain barrier and target pathways implicated in neurodegeneration,  HC Wainwright price target $3,  B. Riley Securities raised price target to $3, does have mixed shelf, be mindful on next spike 

 ✅ XPON entry: $0.70

🎯 PT1: $1.20 – $1.80
🎯 PT2: $1.90 – $2.50
🎯 PT3: $2.60 – $3.50

🚫 Stop: Below $0.60 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup

 company designs, assembles, manufactures, and sells lithium iron phosphate batteries and related accessories in North America, recently announced upcoming release of three lithium battery models, announced batter models available in second half of 2026, company have until 7/28/2026 to bring price above $1 in order to regain nasdaq compliance, does have an additional 180-day extension, does have mixed shelf, be mindful on next spike, 

⏳⏳ SMS swing alert 🚨🚨

✅ VTAK potential entry: $1.00 - $1.10

🎯 Potential PT1: $1.50 - $2.30
🎯 PT2: $2.40 - $2.80
🎯 PT3: $2.90 - $3.50

🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 recently announced launch of Flyte Hops Florida, back to support from recent high, small float, recently received new VIVO purchase order from hospital in Slovenia, Previously entered distribution agreement with FuMedica, and announced two patents to be issued by USPTO, previously received Approval for LockeT in the United Kingdom, announced introduction of LockeT product line into Italy, company specializes in medical device based in US, two main products: VIVO system is a non-invasive, ED cardiac mapping system that integrates ECG and imaging data to help localize ventricular arrhythmia origins before procedures, the other is LockeT device, a suture retention tool designed to optimize vascular closure after percutaneous procedures, aiming to speed up hemostasis and patient recovery,  

✅ IMUX potential entry: $1.10 - $1.15

🎯 Potential PT1: $1.30 - $1.70
🎯 PT2: $1.80 - $2.40
🎯 PT3: $2.50 - $3.40

🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 company focuses on developing therapies for chronic inflammatory and autoimmune diseases targeting conditions including: multiple sclerosis (MS), ulcerative colitis, Crohn’s disease, and other immune-related disorders., upcoming catalysts: 1) top line data from twin phase 3 expected end of 2026, Chardan Capital buy rating, HC Wainwright price target $5, D. Boral Capital price target $8m does have mixed shelf recently filed, be mindful on next spike 

✅ JCSE potential entry: $1.00–$1.10

🎯 PT1: $1.20–$1.80
🎯 PT2: $1.90–$2.50
🎯 PT3: $2.60–$3.60

🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical Setup

 back to support from recent high, company designs and sells industrial cleaning systems and filtration equipment used in manufacturing and food service industries, based out in Singapore 

✅ CMND potential entry: $1.20–$1.30

🎯 PT1: $1.50–$1.80
🎯 PT2: $1.90–$2.40
🎯 PT3: $2.50–$3.50

🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 previously reported positive data for CMND - 100 in alcohol use disorder trial, recently enrolled last patient for first cohort of CMND-100 trial for the treatment of AUD (alcohol use disorder) , recently filed and announced publication of US patent application on binge drinking addiction and compulsive behaviors, also established international patent application for therapy targeting obesity and metabolic syndrome in collaboration with SciSparc, also recently secured IRB approval from Hadassah Medical Center for phase 1/2a trial of Novel AUD treatment, company focuses on the development of psychedelic-derived therapeutics for mental health, neurological disorders, lead candidate, CMND-100 for alcohol use disorder (AUD) 

 ✅ VIVS potential entry: $1.40/1.45
🎯 PT1: $1.60 – $2.20
🎯 PT2: $2.30 – $2.80
🎯 PT3: $2.90 – $3.30
🚫 Stop: Below $1.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to key support form recent high above $3,  previously signed distribution agreements with JCBio in Korea and Tekon Biotech in China for NAMKind Toxicology Services, company focuses on biotech services including testing drugs using 3D human liver and intestine tissue models and AI-driven toxicology platforms

  ✅ ENLV entry: .90
🎯 PT1: 1.20 – 1.80
🎯 PT2: 1.90 – 2.60
🎯 PT3: 2.70 – 3.80
🚫 Stop: Below 0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
recently adoptED RAIN token treasury strategy and advances Allocetra knee osteoarthritis program, recently announced positive 6-month topline data, demonstrating durable and persistent pain reduction and improved function in primary age-rated patients with mod to severe knee osteoarthritis, company focuses on immunotherapy, main program is Allocetra, an off the shelf macrophage-reprogramming therapy intended to restore macrophages to healthy state, treating inflammatory and degenerative disease,  HC Wainwright raised price to $20 from $13  

 ✅ AUID entry: $1.0
🎯 PT1: $1.20 – $1.90
🎯 PT2: $2.00 – $2.40
🎯 PT3: $2.50 – $3.20
🚫 Stop: Below $.85 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

company focuses on biometric identity authentication, recently selected to support retail deployments of kiosks in U.S, recently announced integration with ServiceNow to deliver secure, frictionless identity verification and authentication for contact centers 

 ✅ STEX 🎯 Entry: $1.00 – $1.10
🎯 PT1: $1.40 – $1.80 🎯 PT2: $1.90 – $2.40 🎯 PT3: $2.50 – $2.80
🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup 

 recently announced $GLDY token, previously secured $25M financing for Gold Strategy, also partnership with Chainlink to boost tokenization infrastructure, company focus on bringing physical commodities (especially goal) and other assets on-chain, creating digital/crypto adjacent financial product, Executive Chairman Morgan Lekstrom acquired shares per sec filing on 2/18 , 20,000 , price $2.50, 

 ✅ SNGX potential entry: $1.05 – $1.15

🎯 PT1: $1.40 – $1.80
🎯 PT2: $1.90 – $2.60
🎯 PT3: $2.70 – $3.80

🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 recently received positive orphan drug opinion for SGX945 in Behcet's disease, upcoming catalyst:  ongoing enrollment in phase 3 trial for HyBryte, company specializing in the development and commercialization of therapies for rare and underserved diseases,  Zacks Small-cap price target $35, Alliance Global Partners price target $6, 

 ✅ $MRKR Entry: $1.30–$1.40
🎯 PT1: $1.60–$2.50
🎯 PT2: $2.60–$2.70
🎯 PT3: $2.80–$3.40
🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to support from recent high recently announced positive APOLLO study, recently partnered with Cellpont for MT-601 Manufacturing, company focuses on developing novel T-cell  therapies for hematological malignancies and solid tumors,  HC Wainwright price target  $10, WBB Securities price target $12.50, Canaccord Genuity buy rating price target $8, Brookline buy ratin 

 ✅ FATE Entry: 1.10–1.15
🎯 PT1: 1.40–1.80
🎯 PT2: 1.90–2.50
🎯 PT3: 2.60–3.30
🚫 Stop: Below 1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to support from recent high, company focuses on developing cellular immunotherapies for cancer and autoimmune diseases, Wedbush buy rating, 

 ✅ HUMA entry: .60
🎯 PT1: .80 – 1.20
🎯 PT2: 1.30 – 1.80
🎯 PT3: 1.90 – 2.40
🚫 Stop: Below .55 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to support from recent high, company develops off-the=shelf, implantable bioengineered huma tissues designed to improve treatment of vascular and organ damage, plan to file MAA with Israel Ministry of Health for approval of Acellular Tissue engineered vessel for Arterial Trauma Repair, BTIG price target $3, TD Cowen price target $1, D. Boral capital price target $25, does have mixed shelf, be mindful on next spike 

 ✅ BMEA entry: 1.45–1.50
🎯 PT1: 1.70–2.80
🎯 PT2: 2.90–3.60
🎯 PT3: 3.70–4.50
🚫 Stop: Below 1.20 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to support from recent high, company focuses on oral small molecule therapies for metabolic disease, such as type to diabetes and obesity, lead candidate icovamenib, targets a key protein involved in gene regulation, aiming to improve glycemic control and metabolic outcomes, upcoming catalyst: 1) Q1 2026 to enroll first participant in COVALENT -211 phase IIb trial and provide business update, Director and Officer Rainer Erdtmann recently acquired shares, Interim CEO & director recently bought 667% more shares, Rodman & Renshaw buy rating, D. Boral Capital price target $12.00, HC Wainwright buy rating, Citigroup price target $7 

 ✅ CYN potential entry: $1.50–$1.55
🎯 Potential PT1: $1.80–$2.40
🎯 PT2: $2.50–$2.80
🎯 PT3: $2.90–$4.50
🚫 Potential Stop: Below $1.30 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to near 52wk low from recent high, recent offering 1.93 per share, company featured in $NVDA article about building robots with AI, recently announced commercial contract to deploy DriveMod Tugger at WEG Manufacturing facility in Bluffton, Indiana, recently announced its integration Forklift FMU models into $NVDA Isaac Sim, an open simulation frameowrk for developing autonomous systems, previously expanded dealer network with Candler Automation for DriveMod Tugger in agriculture, announced to deliver additional autonomous vehicles to G&J Pepsi , company focuses on industrial automation, mainly self-driving software and solutions for material handling, warehousing, and industrial fleets, its core products include the Enterprise Autonomy Suite, DriveMod modular autonomous tech and fleet management tools, does have mixed shelf, be mindful on next spike 

 ✅ MXCT entry: $0.70
🎯 PT1: $0.90–$1.40
🎯 PT2: $1.50–$1.80
🎯 PT3: $1.90–$2.50
🚫 Stop: Below $0.65 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 Near 52wk low, recently signed licensing deal with Adicet Bio to support development of gene-edited gamma delta T cell therapies, recent partnership with Ori Biotech to enhance cell therapy manufacturing efficiency, company sells ExPERT electroporation instruments, consumables and services that let biotech/CGT companies deliver DNA/RNA proteins into cells, Stephens & Co price target $6, Craig-Hallum buy rating, price target $5, Stifel Nicolaus buy rating, Zacks Equity Research buy rating, BlackRock increases stake to 9.98% from 7.65% 

 ✅ CRON potential entry: $2.40 - $2.50
🎯 Potential PT1: $2.80 - $3.40
🎯 PT2: $3.50 - $4.30
🎯 PT3: $4.40 - $5.50
🚫 Potential Stop: Below $2.20 or 2%-5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup  

✅ NNOX Entry: $2.4
🎯 PT1: $2.80 – $3.40, 🎯 PT2: $3.50 – $3.80, 🎯 PT3: $3.90 – $4.70
🚫 Stop: Below $2.45 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst Driven | Technical Setup 

 back to near 52wk low, recently announced securing  FDA 510 (K) clearance for TAP2D Image enhancement on Nanox ARC systems, recent new collaboration announcement with Adriamed d.o.o Beograd,  company develops medical imaging systems, D. Boral price target $8, 

 ✅ GNSS entry: $1.70 – $1.75
🎯 PT1: $2.00 – $2.50
🎯 PT2: $2.60 – $3.00
🎯 PT3: $3.10 – $3.90
🚫 Stop: Below $1.50 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
previously  received $2M order from Singapore Navy for LRAD 950nxtS, previously announced $1M follow-on order from nuclear energy operator, also recently entered strategic partnership with Julie Parker Communications, recently received $9M order from teh US Army for its long range acoustic, also recently secured $1.7M follow-on LRAD order from southeast Asia military as part of multi-year program for long range communication device systems, company provides protective communications solutions, serving the federal, state/local government (SLED), enterprise critical infrastructure , globally in >100 countries and all 50 US states, Roth MKM buy rating 

 ✅ CIGL entry: $1.60
🎯 PT1: $2.00 – $2.50
🎯 PT2: $2.60 – $3.30
🎯 PT3: $3.40 – $3.90
🚫 Stop: Below $1.40 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to near 52wk low from recent high, recently entered merger agreement with YOOV Group HOlding in a $600 M deal, previously acquired assets of Software Risk to boost facilities management capabilities, recent partnership with Ryde to open new income streams for drivers in Singapore's growing security and facilities sectors , company provides security and safety solutions to commercial, financial, industrial and government clients, 

  ✅ INAB potential entry: $1.40-1.45
🎯 Potential PT1: $1.70 – $2.20, 🎯 PT2: $2.30 – $2.80, 🎯 PT3: $2.90 – $3.50
🚫 Potential Stop: Below $1.20 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium / catalyst-driven
previously announced patient 009 in phase 1 trial of INB-200 for newly-diagnosed (glioblastoma multiforme) GBM has reached a significant clinical milestone—achieving a 4-year remission, which far surpasses the progression-free outcomes observed in other clinical trials involving IDH-mutant glioma patients, Soumit Roy buy rating, analyst strong boy rating, HC Wainwright price target $6, company focuses on advancing gamma-delta (γδ) T cell-based therapies targeting cancer and autoimmune diseases

  ✅ MAIA potential entry: $1.40
🎯 Potential PT1: $1.80 – $2.30, 🎯 PT2: $2.40 – $2.80, 🎯 PT3: $3.00 – $3.50
🚫 Potential Stop: Below $1.35 or 2%–5% or daily max risk per trade 

🚦 Risk Level: 🟡 Medium / catalyst-driven

,  Near 52wk low from recent high, recent offering price at $1.50 per share, previously secured European patent for cancer therapy, received FDA fast track designation for Ateganosie for its treatment of non-small cell lung cancer, recently announced agreement with ROCHE for cancer therapies, recently announced positive phase 2 clinical trial, Noble Financial price target $14, company focuses on novel telomere-targeting drug called THIO (ateganosine), aimed at telemerase-positive cancers, especially non-small cell lunch cancer (NSCLC) and pediatric high-trade gliomas, operates multiple clinical-stage programs with a team based in Chicago,